- Is Merck A Drug Bellwether?
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Wall of Shame: Fortress Investment's Wes Edens
- Cramer to Geithner: Let FDIC Chair Keep Her Job
- Lightning Round: Boeing, Medtronic, Agrium and More
- Lightning Round OT: Continental, Amylin Pharma and More
- Sell Block: Cramer's Solution for Mortgage-Backed Paper Mess
- Toll Brothers CEO's Housing Outlook
- Making Money Off M&A
- Your First Move For Friday December 5th
- Web Extra: Fast & Furious Trades For Friday
- Pros Say: Job Losses of 425,000; S&P to Fall to 700
- Jobless Data to Put More Pressure on Fed, Bailouts
- Euro Stocks Slip as Miners, Banks Fall
- European Stocks to Open Sharply Lower
- Toshiba to Briefly Halt Chip Output on Weak Demand
- Boeing Mulls Pushing Back Dreamliner Deliveries
- Chief Executive Quits Australian Publisher Fairfax
- Asian Markets Wobble on Gloomy Economic Outlook
- Motor Racing-Honda Pulls Out of Formula One

![]() |
CNBC.com Pharma Stocks |
But there's enough gloom and doom out there so, I'm going to write about a little good news for a bunch of companies in the sector.
The journal "Science" is out with its annual ranking of the best biopharma employers. And Genentech has grabbed the top position again. It had been #1 for the first five years of the survey, but fell to #2 last year, behind Boehringer Ingelheim which dropped to #4 this year. As an aside, shares of DNA were briefly halted for trading this morning. According to Dow Jones it was due to an imbalance.
Our guy on the NYSE floor, Bob Pisani, told me there was some buzz about Roche having secured the financing to do the Genentech deal, but if that were the case wouldn't you think the stock would head in the other direction? Anyway, back to the survey.
Nearly 4,000 people took it in April and May of this year (long before Roche made a play for Genentech, so you can't argue this was a Genentech get-out-the-vote-to-show-how-special-we-really-are campaign). Thirty eight percent of them worked for biotech, 34 percent for pharma, 14 percent for biopharma and the rest in "other life sciences organizations". And they're highly educated and experienced.
Seventy percent had a Ph.D., MD or both. And almost two-thirds had been working in the industry for at least a decade. Sixty-two percent picked the company they work for as the best and they scored companies on nearly two dozen "driving characteristics." This year the top six "driving characteristics" are: 1. innovative leader in the industry, 2. social responsibility, 3. employee loyalty, 4. employer respect for employees, 5. leadership moving the company in the right direction (that one broke into the top six this year) and 6. work and personal values are aligned.
Peter Gwynne, who authored the piece wrote, "For the first time a company outside the mainstream pharmaceutical and biopharmaceutical business has reached the pinnacle of top employers." That'd be Monsanto which jumped from #8 in 2007 to #2 in 2008. The rest of the top 10 are Genzyme, the aforementioned Boehringer, followed by Schering-Plough, Roche, EMD Serono, Inc., Millennium (which has been bought by Japan's Takeda), Gilead Sciences, and Eli Lilly. LLY is so proud of breaking into the top tier that it put out a press release about it. Pfizer and Bristol-Myers Squibb are the only two big pharmas that didn't crack the top 20.
Update: AstraZeneca is no longer an exception. AZN has now joined the rest of the big pharma stocks touching new lows today.
Questions? Comments?



